Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.31 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394613 | 0.93 | ABCC9 (0.31) | ABCC9KCNJ11 | |
| SCHEMBL24822914 | 0.84 | HTT (0.32) | — | |
| SCHEMBL24822912 | 0.78 | — | — | |
| SCHEMBL31394869 | 0.76 | ABCC9 (0.38) | ABCC9KCNJ11 | |
| SCHEMBL16172610 | 0.75 | SLC5A1 (0.34) | — | |
| SCHEMBL17193806 | 0.73 | CYP3A4 (0.36) | — | |
| SCHEMBL309789 | 0.73 | KDM1A (0.36) | BACE1 | |
| SCHEMBL6027545 | 0.73 | RXRA (0.32) | BCHECES1 | |
| SCHEMBL7843935 | 0.70 | BCHE (0.37) | BCHECES1 | |
| SCHEMBL18366143 | 0.69 | RIPK1 (0.35) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | ALCHEMEDICINE, INC. (JP) | 2024-08-29 | — | — | US | disclosed |
| EP-4361146-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | Alchemedicine, Inc. (JP) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022270487-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287053-A1 | COMPOUND, ENDOTHELIN-A RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | EDNRA, EDNRB, ECE1 | BCHE 1770/4885CES1 2912/4885ABCC9 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.